Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Earlier this month, Novavax participated in investor-focused healthcare conferences hosted by Citigroup and Cantor Fitzgerald ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

Novavax (NVAX) closed the most recent trading day at $10.11, moving +1.1% from the previous trading session. The stock ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...

Retail traders are treating Novavax as a cancer-vaccine play today, but the price action shows a single-name bid rather than a sector move. Novavax (NASDAQ:NVAX) stock is up 6% to $9.90 in midday ...

Novavax, Inc.'s valuation remains too high given its reliance on one-off revenues, uncertain royalties, and a complex Sanofi partnership. The company's Q1 2025 earnings were boosted by non-recurring ...

Novavax benefited from this deal, but moving forward, there is far too much uncertainty surrounding it. For one, demand for coronavirus vaccines might no longer be what it once was. That's on top of ...

Novavax raised its annual revenue forecast on ​Thursday, banking on payments related to the vaccine maker's licensing ‌and supply agreements.

Shares of Novavax Inc. NVAX -5.58% shed 3.34% to $9.85 Wednesday, on what proved to be an all-around grim trading session for ...